First and only medicine approved by Health Canada for patients as young as 6-months of age with HoFH, an ultrarare, inherited form of high cholesterolTORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that Health Canada has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lo

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"). XOMA Royalty Corporation

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO™ or tab-cel®) indicated as monotherapy for treatment of adult and pedia

None\n Choosing the right specialty pharmacy partner is critical.When treating rare, chronic and complex conditions, the role of a specialty pharmacy must go beyond simple logistics management, therapy fulfillment and generalized patient care. The ideal partner needs to not only keep pace, but lead the way, in a rapidly evolving care landscape with ever-emerging developments in technology and rare treatments.Finding the right partner in specialty pharmacy care isn’t easy. But here are a f

New “Decision to grant” communications in Canada and Israel For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA30718

– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain’s functional architecture in rare genetic conditions – – Building and growing a license business is an increasingly important pillar of Firefly’s commercial strategy – KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)

Varda Space Industries, which is focused on manufacturing drugs in low Earth orbit, has received more fuel for its endeavors in the form of a $187 million series C fundraising haul. Varda Space Industries, which is leveraging reusable rockets to manufacture drugs in low Earth orbit, has received more fuel for its endeavors in the form of a $187 million series C fundraising haul.The round brings the total capital raised by the El Segundo, California-based startup to $329 million. The late

61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that a real-world, retrospective study demonstrates the benefit of commercial Amtagvi® (lifileucel) in real-world clinical settings for patients w

MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity’s patent exclusivity in the U.S. into 2042. “This dosing regimen patent reflects our commitment to enhancing our intellec

Adding a fourth certified facility within its global network increases operational capacity to better serve international medical markets NASDAQ | TSX: ACB EDMONTON, AB, July 14, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that its dedicated distribution centre located in Brampton, Ontario, has received European Union Good Manufacturing Practice ("EU-GMP") certification, increasing the compa